Sero-prevalence of Coronavirus Disease 2019 (COVID-19) in Healthcare Workers

E

Egyptian Center for Research and Regenerative Medicine

Status

Completed

Conditions

Corona Virus Infection
COVID

Treatments

Biological: Specific anti-SARS-CoV-2 antibodies

Study type

Observational

Funder types

Other

Identifiers

NCT04424017
COVID-19\004

Details and patient eligibility

About

The medical and paramedical staff of the front-line services are potentially exposed to SARS-CoV-2. Therefore, despite the application of standard protective measures, it is possible that a certain number of these personnel have already contracted SARS-CoV-2, including in its asymptomatic form. Serological testing in this context would be useful for deploying immune healthcare workers as to limit the risk of viral infection and transmission. Therefore, it is of utmost importance to prove that the serological response entails the production of neutralizing antibodies.

Enrollment

1,546 patients

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Not previously diagnosed with COVID-19 except for convalescents
  • Not currently symptomatic with fever or respiratory symptoms (cough, dyspnea)

Exclusion criteria

  • Patients with fever or respiratory symptoms (cough, dyspnea)
  • Refusal to give informed consent, or contraindication to venipuncture.

Trial design

1,546 participants in 3 patient groups

Healthcare workers (HCWs)
Treatment:
Biological: Specific anti-SARS-CoV-2 antibodies
Healthy blood donors and healthy subjects in blood bank
Treatment:
Biological: Specific anti-SARS-CoV-2 antibodies
Convalescents
Treatment:
Biological: Specific anti-SARS-CoV-2 antibodies

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems